
After almost three years, the Food & Drug Administration has approved Omnitrope (somatropin, Sandoz) as a follow-on version of Pfizer's Genotropin. "Its approval is beneficial for everyone. It also increases competition in the growth hormone market, which will hopefully reduce the price of growth hormones," stated Anita Siu, Pharm.D. and clinical neonatal/ pediatric pharmacotherapy specialist and assistant clinical professor at the Ernest Mario School of Pharmacy, Rutgers, the state university of New Jersey.